BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Regorafenib readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Regorafenib\, from ClinicalTrials.gov est
 imates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05370807-2058@assetmemo.bio
DTSTAMP:20261121T004103Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Regorafenib: Phase 2 readout est. (NCT05370807)
DESCRIPTION:Regorafenib\, phase 2.\nStudy: A Clinical Trial of Regorafenib 
 in Patients With Pretreated Advanced Melanoma\nEstimated primary completio
 n: December 2026. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/reg
 orafenib#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT05370807
URL:https://assetmemo.bio/drug/regorafenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07567222-2058@assetmemo.bio
DTSTAMP:20261121T004103Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Regorafenib: Phase 1 readout est. (NCT07567222)
DESCRIPTION:Regorafenib\, phase 1.\nStudy: Clinical Study of Novel Therapeu
 tic Vaccine for Advanced Solid Tumors\nEstimated primary completion: 31 De
 cember 2026. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/regorafe
 nib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 07567222
URL:https://assetmemo.bio/drug/regorafenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04503694-2058@assetmemo.bio
DTSTAMP:20261121T004103Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Regorafenib: Phase 2 readout est. (NCT04503694)
DESCRIPTION:Regorafenib\, phase 2.\nStudy: Neoadjuvant Regorafenib in Combi
 nation With Nivolumab and Short-course Radiotherapy in Stage II-III Rectal
  Cancer\nEstimated primary completion: 31 December 2026. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/regorafenib#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT04503694
URL:https://assetmemo.bio/drug/regorafenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06099821-2058@assetmemo.bio
DTSTAMP:20261121T004103Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Regorafenib: Phase 2 readout est. (NCT06099821)
DESCRIPTION:Regorafenib\, phase 2.\nStudy: KN046 Plus Regorafenib or Apatin
 ib in MSI-H Digestive System Cancers Resistant to PD-1/PD-L1 Blockade\nEst
 imated primary completion: 31 December 2026. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/regorafenib#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT06099821
URL:https://assetmemo.bio/drug/regorafenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05366816-2058@assetmemo.bio
DTSTAMP:20261121T004103Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Regorafenib: Phase 2 readout est. (NCT05366816)
DESCRIPTION:Regorafenib\, phase 2\, Gastrointestinal Stromal Tumor.\nStudy:
  ctDNA-Guided Sunitinib And Regorafenib Therapy for GIST\nEstimated primar
 y completion: 31 December 2026. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/regorafenib#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT05366816
URL:https://assetmemo.bio/drug/regorafenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04757363-2058@assetmemo.bio
DTSTAMP:20261121T004103Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Regorafenib: Phase 2 readout est. (NCT04757363)
DESCRIPTION:Regorafenib\, phase 2.\nStudy: A Study of Nivolumab Combined Wi
 th FOLFOX and Regorafenib in People Who Have HER2-Negative Esophagogastric
  Cancer\nEstimated primary completion: February 2027. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/regorafenib#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT04757363
URL:https://assetmemo.bio/drug/regorafenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06047379-2058@assetmemo.bio
DTSTAMP:20261121T004103Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Regorafenib: Phase 1/2 readout est. (NCT06047379)
DESCRIPTION:Regorafenib\, phase 1/2\, Colorectal Cancer.\nStudy: Safety and
  Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant\, Glioblastoma
  IDH-wildtype or Brain Metastasis\nEstimated primary completion: 28 Februa
 ry 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/regorafenib#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0604
 7379
URL:https://assetmemo.bio/drug/regorafenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06558773-2058@assetmemo.bio
DTSTAMP:20261121T004103Z
DTSTART;VALUE=DATE:20270301
DTEND;VALUE=DATE:20270302
SUMMARY:Regorafenib: Phase 2 readout est. (NCT06558773)
DESCRIPTION:Regorafenib\, phase 2\, Colorectal Cancer.\nStudy: GSL Syntheta
 se Inhibitor Plus Immune Checkpoint Inhibitor and/or Regorafenib in Previo
 usly Treated pMMR/MSS CRC.\nEstimated primary completion: 1 March 2027. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/regorafenib#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT06558773
URL:https://assetmemo.bio/drug/regorafenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04701476-2058@assetmemo.bio
DTSTAMP:20261121T004103Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Regorafenib: Phase 2 readout est. (NCT04701476)
DESCRIPTION:Regorafenib\, phase 2\, Colorectal Cancer.\nStudy: TATE and Pem
 brolizumab (MK3475) in mCRC and NSCLC\nEstimated primary completion: 31 Ma
 rch 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/regorafenib
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT047
 01476
URL:https://assetmemo.bio/drug/regorafenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05794971-2058@assetmemo.bio
DTSTAMP:20261121T004103Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Regorafenib: Phase 3 readout est. (NCT05794971)
DESCRIPTION:Regorafenib\, phase 3\, Colorectal Cancer.\nStudy: Regorafenib 
 Combined With Irinotecan Drug-Eluting Beads for Colorectal Cancer Liver Me
 tastases\nEstimated primary completion: 31 March 2027. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/regorafenib#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT05794971
URL:https://assetmemo.bio/drug/regorafenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05830084-2058@assetmemo.bio
DTSTAMP:20261121T004103Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Regorafenib: Phase 1 readout est. (NCT05830084)
DESCRIPTION:Regorafenib\, phase 1.\nStudy: Phase Ib / Regorafenib With Conv
 entional Chemotherapy/Newly Diagnosed Patients/ Multimetastatic Ewing Sarc
 oma\nEstimated primary completion: April 2027. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/regorafenib#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT05830084
URL:https://assetmemo.bio/drug/regorafenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06930118-2058@assetmemo.bio
DTSTAMP:20261121T004103Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Regorafenib: Phase 2 readout est. (NCT06930118)
DESCRIPTION:Regorafenib\, phase 2\, Colorectal Cancer.\nStudy: The Aim of T
 his Study is to Assess the Efficacy and Safety of Chidamide\, Regorafenib 
 in Combination With Iparomlimab and Tuvonralimab for the Treatment of Adva
 nced Colorectal Cancer in Third-line Therapy and Subsequent Lines.\nEstima
 ted primary completion: 30 April 2027. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/regorafenib#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT06930118
URL:https://assetmemo.bio/drug/regorafenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07071961-2058@assetmemo.bio
DTSTAMP:20261121T004103Z
DTSTART;VALUE=DATE:20270501
DTEND;VALUE=DATE:20270502
SUMMARY:Regorafenib: Phase 2 readout est. (NCT07071961)
DESCRIPTION:Regorafenib\, phase 2\, Colorectal Cancer.\nStudy: Regorafenib 
 (Reg) and Lorigerlimab (Lor)\, RELO Regimen\, in Treatment of High-risk Pa
 tients With Colorectal Cancer With Radiographic Occult Molecular Residual 
 Disease After End of Established Definitive Therapy [ReLOAD Trial]\nEstima
 ted primary completion: 1 May 2027. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/regorafenib#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT07071961
URL:https://assetmemo.bio/drug/regorafenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07040228-2058@assetmemo.bio
DTSTAMP:20261121T004103Z
DTSTART;VALUE=DATE:20270530
DTEND;VALUE=DATE:20270531
SUMMARY:Regorafenib: Phase 1/2 readout est. (NCT07040228)
DESCRIPTION:Regorafenib\, phase 1/2.\nStudy: A Phase Ib/II Clinical Study o
 f Regorafenib Combined With Toripalimab and Albumin-bound Paclitaxel for t
 he Third-line Treatment of Advanced Pancreatic Cancer\nEstimated primary c
 ompletion: 30 May 2027. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/regorafenib#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT07040228
URL:https://assetmemo.bio/drug/regorafenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07559864-2058@assetmemo.bio
DTSTAMP:20261121T004103Z
DTSTART;VALUE=DATE:20270601
DTEND;VALUE=DATE:20270602
SUMMARY:Regorafenib: Phase 2 readout est. (NCT07559864)
DESCRIPTION:Regorafenib\, phase 2\, Gastrointestinal Stromal Tumor.\nStudy:
  Comparing Regorafenib Combined With Envafolimab to Physician's Choice in 
 Patients With Metastatic Gastrointestinal Stromal Tumors Harboring KIT Exo
 n 17 Mutations Refractory to Standard Treatment\nEstimated primary complet
 ion: 1 June 2027. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/reg
 orafenib#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT07559864
URL:https://assetmemo.bio/drug/regorafenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06772233-2058@assetmemo.bio
DTSTAMP:20261121T004103Z
DTSTART;VALUE=DATE:20270730
DTEND;VALUE=DATE:20270731
SUMMARY:Regorafenib: Phase 2 readout est. (NCT06772233)
DESCRIPTION:Regorafenib\, phase 2\, Gastrointestinal Stromal Tumor.\nStudy:
  A Study of Regorafenib Combined With Envafolimab for Metastatic Gastroint
 estinal Stromal Tumors With Kit Gene Exon 17 Mutation That Failed Standard
  Treatment\nEstimated primary completion: 30 July 2027. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/regorafenib#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT06772233
URL:https://assetmemo.bio/drug/regorafenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07483684-2058@assetmemo.bio
DTSTAMP:20261121T004103Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Regorafenib: Phase 3 readout est. (NCT07483684)
DESCRIPTION:Regorafenib\, phase 3\, Colorectal Cancer.\nStudy: A Clinical S
 tudy to Evaluate Injection TQB2102 for the Treatment of Patients With HER2
  IHC3+ Advanced Colorectal Cancer Who Progressed After Treatment With Oxal
 iplatin\, Irinotecan and Fluoropyrimidine-Based Drugs\nEstimated primary c
 ompletion: August 2027. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/regorafenib#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT07483684
URL:https://assetmemo.bio/drug/regorafenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07115550-2058@assetmemo.bio
DTSTAMP:20261121T004103Z
DTSTART;VALUE=DATE:20270826
DTEND;VALUE=DATE:20270827
SUMMARY:Regorafenib: Phase na readout est. (NCT07115550)
DESCRIPTION:Regorafenib\, phase na\, Hepatocellular Carcinoma.\nStudy: A Si
 ngle-center\, Single-arm\, Phase II Clinical Study of Iparomlimab and Tuvo
 nralimab Injection Combined With Regorafenib in the Treatment of Advanced 
 Second-line or Above Hepatocellular Carcinoma\nEstimated primary completio
 n: 26 August 2027. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/re
 gorafenib#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT07115550
URL:https://assetmemo.bio/drug/regorafenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02925234-2058@assetmemo.bio
DTSTAMP:20261121T004103Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Regorafenib: Phase 2 readout est. (NCT02925234)
DESCRIPTION:Regorafenib\, phase 2.\nStudy: The Drug Rediscovery Protocol (D
 RUP Trial)\nEstimated primary completion: September 2027. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/regorafenib#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT02925234
URL:https://assetmemo.bio/drug/regorafenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02955940-2058@assetmemo.bio
DTSTAMP:20261121T004103Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Regorafenib: Phase 2 readout est. (NCT02955940)
DESCRIPTION:Regorafenib\, phase 2\, Colorectal Cancer.\nStudy: An Open-Labe
 l Study to Enable Continued Treatment Access for Subjects Previously Enrol
 led in Studies of Ruxolitinib\nEstimated primary completion: 30 September 
 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/regorafenib#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0295594
 0
URL:https://assetmemo.bio/drug/regorafenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07343791-2058@assetmemo.bio
DTSTAMP:20261121T004103Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Regorafenib: Phase 1 readout est. (NCT07343791)
DESCRIPTION:Regorafenib\, phase 1\, Colorectal Cancer.\nStudy: Efficacy and
  Safety Study of DC-CIK Cell Therapy Combined With Epaloliposide\, Vortexi
 l\, and Regorafenib as Third-line Treatment for Advanced Colorectal Cancer
 .\nEstimated primary completion: 30 November 2027. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/regorafenib#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT07343791
URL:https://assetmemo.bio/drug/regorafenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07384377-2058@assetmemo.bio
DTSTAMP:20261121T004103Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Regorafenib: Phase 3 readout est. (NCT07384377)
DESCRIPTION:Regorafenib\, phase 3\, Colorectal Cancer.\nStudy: JSKN003 Vers
 us Physician Choiced Treatment in Patients With HER2-positive and Advanced
  Colorectal Cancer Who Had Failed to Respond to Oxaliplatin\, 5-Fu\, and I
 rinotecan\nEstimated primary completion: 30 November 2027. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/regorafenib#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT07384377
URL:https://assetmemo.bio/drug/regorafenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06283134-2058@assetmemo.bio
DTSTAMP:20261121T004103Z
DTSTART;VALUE=DATE:20271201
DTEND;VALUE=DATE:20271202
SUMMARY:Regorafenib: Phase 1 readout est. (NCT06283134)
DESCRIPTION:Regorafenib\, phase 1\, Colorectal Cancer.\nStudy: A Clinical S
 tudy of BioTTT001 in Combination With Toripalimab and Regorafenib in Patie
 nts With Colorectal Cancer\nEstimated primary completion: 1 December 2027.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/regorafenib#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT06283134
URL:https://assetmemo.bio/drug/regorafenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07148427-2058@assetmemo.bio
DTSTAMP:20261121T004103Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:Regorafenib: Phase 2 readout est. (NCT07148427)
DESCRIPTION:Regorafenib\, phase 2.\nStudy: Immunotherapy Combined With Anti
 -angiogenic Therapy and Chemotherapy for Gastric/Gastroesophageal Junction
  Adenocarcinoma\nEstimated primary completion: 30 December 2027. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/regorafenib#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT07148427
URL:https://assetmemo.bio/drug/regorafenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07750041-2058@assetmemo.bio
DTSTAMP:20261121T004103Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Regorafenib: Phase 1/2 readout est. (NCT07750041)
DESCRIPTION:Regorafenib\, phase 1/2\, Colorectal Cancer.\nStudy: A Phase Ib
 /II Study of SYS6090 Combination Therapy in Advanced Colorectal Cancer\nEs
 timated primary completion: 31 December 2027. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/regorafenib#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT07750041
URL:https://assetmemo.bio/drug/regorafenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06992648-2058@assetmemo.bio
DTSTAMP:20261121T004103Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Regorafenib: Phase 3 readout est. (NCT06992648)
DESCRIPTION:Regorafenib\, phase 3\, Colorectal Cancer.\nStudy: Trifluridine
 /Tipiracil Plus Regorafenib vs Trifluridine/Tipiracil Plus Bevacizumab for
  Refractory Metastatic Colorectal Cancer\nEstimated primary completion: 31
  December 2027. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/regor
 afenib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT06992648
URL:https://assetmemo.bio/drug/regorafenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07495579-2058@assetmemo.bio
DTSTAMP:20261121T004103Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Regorafenib: Phase 2 readout est. (NCT07495579)
DESCRIPTION:Regorafenib\, phase 2\, Hepatocellular Carcinoma.\nStudy: Lenva
 tinib or Regorafenib for Advanced Hepatocellular Carcinoma After Immunothe
 rapy (REVIVE)\nEstimated primary completion: April 2028. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/regorafenib#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT07495579
URL:https://assetmemo.bio/drug/regorafenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06246643-2058@assetmemo.bio
DTSTAMP:20261121T004103Z
DTSTART;VALUE=DATE:20280427
DTEND;VALUE=DATE:20280428
SUMMARY:Regorafenib: Phase 2 readout est. (NCT06246643)
DESCRIPTION:Regorafenib\, phase 2.\nStudy: A Study of Continued Treatment W
 ith Regorafenib in Participants With Solid Tumors Who Have Participated in
  Other Bayer Studies\nEstimated primary completion: 27 April 2028. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/regorafenib#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT06246643
URL:https://assetmemo.bio/drug/regorafenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07514455-2058@assetmemo.bio
DTSTAMP:20261121T004103Z
DTSTART;VALUE=DATE:20280531
DTEND;VALUE=DATE:20280601
SUMMARY:Regorafenib: Phase 2 readout est. (NCT07514455)
DESCRIPTION:Regorafenib\, phase 2\, Hepatocellular Carcinoma.\nStudy: Regor
 afenib After Treatment Failure of First Line Immune Checkpoint Inhibitor T
 reatment in Advanced Hepatocellular Carcinoma Patients\nEstimated primary 
 completion: 31 May 2028. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/regorafenib#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT07514455
URL:https://assetmemo.bio/drug/regorafenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07514429-2058@assetmemo.bio
DTSTAMP:20261121T004103Z
DTSTART;VALUE=DATE:20280531
DTEND;VALUE=DATE:20280601
SUMMARY:Regorafenib: Phase 2 readout est. (NCT07514429)
DESCRIPTION:Regorafenib\, phase 2\, Hepatocellular Carcinoma.\nStudy: Regor
 afenib After Failure of Lenvatinib in Patients With Unresectable HCC: The 
 RELEVANT-HCC Trial\nEstimated primary completion: 31 May 2028. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/regorafenib#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT07514429
URL:https://assetmemo.bio/drug/regorafenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03970447-2058@assetmemo.bio
DTSTAMP:20261121T004103Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Regorafenib: Phase 2/3 readout est. (NCT03970447)
DESCRIPTION:Regorafenib\, phase 2/3.\nStudy: A Trial to Evaluate Multiple R
 egimens in Newly Diagnosed and Recurrent Glioblastoma\nEstimated primary c
 ompletion: June 2028. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /regorafenib#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT03970447
URL:https://assetmemo.bio/drug/regorafenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03844620-2058@assetmemo.bio
DTSTAMP:20261121T004103Z
DTSTART;VALUE=DATE:20280831
DTEND;VALUE=DATE:20280901
SUMMARY:Regorafenib: Phase 2 readout est. (NCT03844620)
DESCRIPTION:Regorafenib\, phase 2\, Colorectal Cancer.\nStudy: Circulating 
 Cell-Free Tumor DNA Testing in Guiding Treatment for Patients With Advance
 d or Metastatic Colorectal Cancer\nEstimated primary completion: 31 August
  2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/regorafenib#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT038446
 20
URL:https://assetmemo.bio/drug/regorafenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06887218-2058@assetmemo.bio
DTSTAMP:20261121T004103Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Regorafenib: Phase 2 readout est. (NCT06887218)
DESCRIPTION:Regorafenib\, phase 2\, Colorectal Cancer.\nStudy: 5-Fluorourac
 il/Leucovorin (5FU/LV) in Combination With Regorafenib in Patients With Me
 tastatic Colorectal Cancer\nEstimated primary completion: December 2028. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/regorafenib#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT06887218
URL:https://assetmemo.bio/drug/regorafenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06275919-2058@assetmemo.bio
DTSTAMP:20261121T004103Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Regorafenib: Phase 2 readout est. (NCT06275919)
DESCRIPTION:Regorafenib\, phase 2.\nStudy: Regorafenib for Recurrent Mening
 ioma (MIRAGE Trial)\nEstimated primary completion: December 2028. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/regorafenib#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT06275919
URL:https://assetmemo.bio/drug/regorafenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05462613-2058@assetmemo.bio
DTSTAMP:20261121T004103Z
DTSTART;VALUE=DATE:20291130
DTEND;VALUE=DATE:20291201
SUMMARY:Regorafenib: Phase 2/3 readout est. (NCT05462613)
DESCRIPTION:Regorafenib\, phase 2/3\, Colorectal Cancer.\nStudy: Regorafeni
 b With Low-dose Chemotherapies and Aspirin Followed by Standard Chemothera
 pies in Metastatic Colorectal Cancer\nEstimated primary completion: Novemb
 er 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/regorafenib#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0546
 2613
URL:https://assetmemo.bio/drug/regorafenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04625907-2058@assetmemo.bio
DTSTAMP:20261121T004103Z
DTSTART;VALUE=DATE:20300630
DTEND;VALUE=DATE:20300701
SUMMARY:Regorafenib: Phase 1/2 readout est. (NCT04625907)
DESCRIPTION:Regorafenib\, phase 1/2.\nStudy: FaR-RMS: An Overarching Study 
 for Children and Adults With Frontline and Relapsed RhabdoMyoSarcoma\nEsti
 mated primary completion: June 2030. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/regorafenib#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT04625907
URL:https://assetmemo.bio/drug/regorafenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05159245-2058@assetmemo.bio
DTSTAMP:20261121T004103Z
DTSTART;VALUE=DATE:20311125
DTEND;VALUE=DATE:20311126
SUMMARY:Regorafenib: Phase 2 readout est. (NCT05159245)
DESCRIPTION:Regorafenib\, phase 2.\nStudy: The Finnish National Study to Fa
 cilitate Patient Access to Targeted Anti-cancer Drugs\nEstimated primary c
 ompletion: 25 November 2031. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/regorafenib#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT05159245
URL:https://assetmemo.bio/drug/regorafenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06087263-2058@assetmemo.bio
DTSTAMP:20261121T004103Z
DTSTART;VALUE=DATE:20320701
DTEND;VALUE=DATE:20320702
SUMMARY:Regorafenib: Phase 2 readout est. (NCT06087263)
DESCRIPTION:Regorafenib\, phase 2\, Gastrointestinal Stromal Tumor.\nStudy:
  Phase 2 Study to Evaluate the Efficacy of Regorafenib in Specific GIST Mu
 tation Subsets (KIT Exon 17\, 18\, or 14 Mutation and SDHB Deficient GIST)
  in the Post-imatinib Second-line Setting.\nEstimated primary completion: 
 1 July 2032. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/regorafe
 nib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 06087263
URL:https://assetmemo.bio/drug/regorafenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
